Addition of ramucirumab to docetaxel in NSCLC post-platinum setting led to an improvement of overall survival in the REVEL study.
This analysis examined quality of life as assessed by the Lung Cancer Symptom Scale (LCSS) and clinician-reported functional status.
Time to deterioration for all LCSS scores and time to PS ≥2 were similar in both arms.
Adding ramucirumab to docetaxel in NSCLC post-platinum setting did not impair patient quality of life, symptoms or functioning.